Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Short Interest Update

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) was the target of a large growth in short interest during the month of May. As of May 29th, there was short interest totaling 514,441 shares, a growth of 494.7% from the May 14th total of 86,503 shares. Based on an average trading volume of 335,136 shares, the days-to-cover ratio is currently 1.5 days. Approximately 1.1% of the company’s shares are short sold.

Insiders Place Their Bets

In related news, major shareholder Sr One Capital Management, Llc sold 1,780 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $18.00, for a total transaction of $32,040.00. Following the completion of the sale, the insider directly owned 440,981 shares of the company’s stock, valued at approximately $7,937,658. This trade represents a 0.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Dimension Capital Ii, L.P. acquired 1,111,111 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The shares were acquired at an average cost of $18.00 per share, with a total value of $19,999,998.00. Following the completion of the transaction, the director directly owned 3,333,516 shares in the company, valued at approximately $60,003,288. The trade was a 50.00% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders acquired 4,183,777 shares of company stock worth $75,319,986.

Analysts Set New Price Targets

Several equities analysts have weighed in on ODTX shares. TD Cowen started coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They issued a “buy” rating for the company. JPMorgan Chase & Co. started coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They issued an “overweight” rating and a $26.00 target price for the company. Wedbush started coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $30.00 target price for the company. Oppenheimer started coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $40.00 target price for the company. Finally, Wall Street Zen raised Odyssey Therapeutics to a “hold” rating in a research report on Saturday, May 16th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Odyssey Therapeutics Stock Performance

ODTX stock traded up $0.39 during trading on Friday, hitting $17.20. 89,169 shares of the company’s stock were exchanged, compared to its average volume of 313,741. Odyssey Therapeutics has a 52-week low of $15.35 and a 52-week high of $20.30.